A protein kinase inhibitor, H-7, blocks naloxone-precipitated changes in dopamine and its metabolites in the brains of opioid-dependent rats

Brain Research Bulletin

Volumn 52, Issue 5, 2000, Pages 363-369

  Tokuyama, Shogo ^a   Ho, Ing K ^b   Yamamoto, Toshinori ^a  

^a SHOWA UNIVERSITY   (Japan)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Butorphanol; Dopamine; H 7; Morphine; Opioid physical dependence; Protein kinases

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 3,4 DIHYDROXYPHENYLACETIC ACID; BUTORPHANOL; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOPAMINE; HOMOVANILLIC ACID; MORPHINE; NALOXONE; PROTEIN KINASE C;

ANIMAL MODEL; ARTICLE; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOSE RESPONSE; ENZYME ACTIVITY; LIMBIC CORTEX; MALE; MESENCEPHALON; NONHUMAN; OPIATE ADDICTION; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; WITHDRAWAL SYNDROME;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; BUTORPHANOL; CEREBRAL CORTEX; CORPUS STRIATUM; DOPAMINE; ENZYME INHIBITORS; HOMOVANILLIC ACID; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENTRICULAR; LIMBIC SYSTEM; MALE; MESENCEPHALON; MORPHINE; NALOXONE; OPIOID-RELATED DISORDERS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0034662217     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(00)00273-2     Document Type: Article

References (42)

1. Ahtee L., Attila P., Lauhakangas V., Solkinen A., Sipila J. The fall of homovanilic acid and 5-hydroxyindoleacetic acid concentrations in brain of mice withdrawn from repeated morphine treatment and their restoration by acute morphine administration. J. Neural Transm. 68:1987;63-78.
2. Ahtee L. Catalepsy and stereotyped behaviour in rats treated chronically with methadone Relation to brain homovanilic acid content . J. Pharm. Pharmacol. 25:1973;649-651.
3. Ahtee L. Catalepsy and stereotypies in rats treated with methadone Relation to striatal dopamine . Eur. J. Pharmacol. 27:1974;221-230.
4. Baume de la S., Patey G., Marcais H., Protais P., Costentin J., Schwartz J.-C. Changes in dopamine receptors in mouse striatum following morphine treatments. Life Sci. 24:1979;2333-2342.
5. 3H-SCH 23390 following morphine withdrawal from tolerant and physically dependent rats. J. Pharmacol. Exp. Ther. 252:1990;901-907.
6. Carlson D.S., Seeger T.F. Interaction of opiates with dopamine receptors Receptor binding and behavioral assays . Pharmacol. Biochem. Behav. 16:1982;119-124.
7. Feng Y.Z., Zhang T., Rockhold R.W., Ho I.K. Opioid receptor subtypes modulate pontaine excitatory amino acid (EAA) levels differently in butrphanol and morphine dependence. Soc. Neurosci. Abstr. 20:1994;1232.
8. Finne U., Kataja C., Pesonen U., Kiianmaa K., Attila M., Ahtee L. Rotational behaviour in rats chronically treated with morphine during treatment and after withdrawal. Acta Pharmacol. Toxicol. 41:1977;46.
9. Garcia-Sevilla J.A., Ahtee L., Magnusson T., Carlsson A. Opiate-receptor mediated changes in monoamine synthesis in rat brain. J. Pharm. Pharmacol. 30:1978;613-621.
10. Garland L.G., Bonser R.W., Thompson N.T. Protein kinase C inhibitors are not selective. Trends Pharmacol. Sci. 8:1987;334.
11. Giambalvo C.T. Protein kinase C and dopamine transport-1. Effects of amphetamine in vivo. Neuropharmacology. 31:1992;1201-1210.
12. 3H]dopa in various regions of the brain. J. Neurochem. 13:1966;655-669.
13. Gucker S., Bidlack J.M. Protein kinase C activation increases the rate and magnitude of agonist-induced δ-opioid receptor down-regulation in NG108-15 cells. Mol. Pharmacol. 42:1992;656-665.
14. 2 (CTOP) in mice. Eur. J. Pharmacol. 150:1988;355-360.
15. Hidaka H., Inagaki M., Kawamoto S., Sasaki Y. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide protein kinase and protein kinase C. Biochem. 23:1984;5036-5041.
16. Horan P.J., Ho I.K. Comparative pharmacological and biochemical studies between butorphanol and morphine. Pharmacol. Biochem. Behav. 34:1989;847-854.
17. Ingram S.L., Vaughan C.W., Bagley E.E., Connor M., Christie M.J. Enhanced opioid efficacy in opioid dependence is caused by an altered signal transduction pathway. J. Neurosci. 18:1998;10269-10276.
18. Jaw S.P., Hoskins B., Ho I.K. Involvement of δ-opioid receptors in physical dependence on butorphanol. Eur. J. Pharmacol. 240:1993;67-72.
19. Jaw S.P., Hoskins B., Ho I.K. Opioid antagonists and butorphanol dependence. Pharmacol. Biochem. Behav. 44:1993;497-500.
20. Jaw S.P., Makimura M., Hoskins B., Ho I.K. Effect of nor-binaltorphimine on butorphanol dependence. Eur. J. Pharmacol. 239:1993;133-140.
21. 2 receptors in rat substantia nigra neurones. J. Physiol. 401:1988;437-453.
22. Li Y., Roerig S.C. Alteration of spinal protein kinase C expression and kinetics in morphine, but not clonidine, tolerance. Biochem. Pharmacol. 58:1999;493-501.
23. Mavridis M., Besson M.J. Dopamine-opiate interaction in the regulation of neostriatal and pallidal neuronal activity as assessed by opioid precursor peptides and glutamate decarboxylase messenger RNA expression. Neuroscience. 92:1999;945-966.
24. Miller R.J. Peptides as neurotransmitters Focus on the enkephalin and endorphins . Pharmacol. Ther. 12:1981;73-108.
25. 2 opioid receptors in the development of morphine dependence in mice. J. Pharmacol. Exp. Ther. 264:1993;1141-1145.
26. Narita M., Makimura M., Feng Y.Z., Hoskins B., Ho I.K. Influence of chronic morphine treatment on protein kinase C activity Comparison with butorphanol and implication for opioid tolerance . Brain Res. 650:1994;175-179.
27. Nestler E.J., Hope B.T., Widnell K.L. Drug addiction A model for molecular basis of neural plasticity . Neuron. 11:1993;995-1006.
28. Nestler E.J., Tallman J.F. Chronic morphine treatment increases cyclic AMP-dependent protein kinase activity in the rat locus coeruleus. Mol. Pharmacol. 33:1988;127-132.
29. Paxinos G., Watson C. The rat brain in stereotaxic coordinates, 2nd ed. 1986;Academic Press, Orlando, FL.
30. 3H)-spiroperidol binding and stereotype behavior by cyclo (leu-gly). Life Sci. 30:1982;1573-1580.
31. 14C-Catecholamine synthesis in mouse brain during morphine withdrawal. Nature. 240:1972;153-155.
32. Shearman M.S., Sekiguchi K., Nishizuka Y. Modulation of ion channel activity A key function of the protein kinase C enzyme family . Pharmacol. Rev. 41:1989;211-237.
33. Steketee J.D. Injection of the protein kinase inhibitor H7 into the A10 dopamine region blocks the acute response to cocaine Behavioral and in vivo microdialysis studies . Neuropharmacology. 32:1993;1289-1297.
34. Terwilliger R.Z., Beitner-Johnson D., Sevarino K.A., Crain S.M., Nestler E.J. A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Res. 548:1991;100-110.
35. 2+ channel blocker, diltiazem, prevents physical dependence and the enhancement of protein kinase C activity by opioid infusion in rats. Eur. J. Pharmacol. 279:1995;93-98.
36. Tokuyama S., Feng Y.Z., Wakabayashi H., Ho I.K. Possible involvement of protein kinases in physical dependence on opioids Studies using protein kinase inhibitors, H-7 and H-8 . Eur. J. Pharmacol. 284:1995;101-107.
37. 2+ channel blocker, on naloxone-increased glutamate levels in the locus coeruleus of opioid-dependent rats. Brain Res. 722:1996;212-216.
38. Tokuyama S., Wakabayashi H., Ho I.K. Direct evidence for a role of glutamate in the expression of the opioid withdrawal syndrome. Eur. J. Pharmacol. 295:1996;123-129.
39. Tokuyama S., Wakabayashi H., Hoskins B., Ho I.K. Naloxone-precipitated changes in biogenic amines and their metabolites in various brain regions of butorphanol-dependent rats. Pharmacol. Biochem. Behav. 54:1996;461-468.
40. Tokuyama S., Zhu H., Wakabayashi H., Feng Y.Z., Ho I.K. The role of glutamate in the locus coeruleus during opioid withdrawal and effects of H-7, a protein kinase inhibitor, on the action of glutamate in rats. J. Biomed. Sci. 5:1998;45-53.
41. Wagner E.J., Zhang G., Lagrange A.H., Ronnekleiv O.K., Kelly M.J. Tolerance to mu-opioid receptor agonists but not cross-tolerance to gamma-aminobutyric acid receptor agonists in arcuate A12 dopamine neurons with chronic morphine treatment. J. Pharmacol. Exp. Ther. 280:1997;1057-1064.
42. Wakabayashi H., Tokuyama S., Ho I.K. Simultaneous measurement of biogenic amines and their metabolites in rat brain regions after acute administration of and abrupt withdrawal from butorphanol or morphine. Neurochem. Res. 20:1995;1179-1185.